In this study, we found that MET/EGFR and their downstream signaling ERK1/2 and AKT may be the targets of FAM83H-AS1 in lung cancer, indicating that FAM83H-AS1 may be a potential therapeutic target. This evidence concerns the gene MAPK3 and lung cancer.